linjc16/ctgov huggingface dataset:
Invasive Pneumococcal Disease Study

Study Overview
=================
Brief Summary
-----------------
After 7 then 13 valent pneumococcal conjugate vaccine implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.

Official Title
-----------------
Population-based Nationwide Study on Invasive Pneumococcal Infections Among Children (0-18 Years) in France

Conditions
-----------------
Pneumococcal Infections, Pneumococcal Conjugate Vaccine, Antibiotic Treatment, Mortality

Intervention / Treatment
-----------------
* Other: observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood PCR. Exclusion Criteria: Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort of invasive pneumococcal disease in children<br> | Other: observational study<br>* observational study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of invasive pneumococcal disease | Number of severe cases according to age and pneumococcal serotypes distribution | before hospital discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of vaccines | Number of invasive pneumococcal disease according to vaccine serotypes | before hospital discharge |
Visco-Circumferential-Suture-Trabeculotomy Versus Trabeculotomy

Study Overview
=================
Brief Summary
-----------------
comparing outcomes of Visco-Circumferential-Suture-Trabeculotomy in primary congenital glaucoma to trabeculotomy

Detailed Description
-----------------
prospective randomized interventional study conducted on infants below the age of 2 years with PCG attending the outpatient clinic of Mansoura Ophthalmic Center of Mansoura University were recruited to compare the long-term surgical outcomes of this proposed technique (VCST) and rigid probe VT in patients with PCG.

Official Title
-----------------
Surgical Outcomes of Visco-Circumferential-Suture-Trabeculotomy in Primary Congenital Glaucoma: A 3-year Randomized Controlled Study

Conditions
-----------------
Primary Congenital Glaucoma

Intervention / Treatment
-----------------
* Procedure: trabeculotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infants below the age of 2 years with PCG Exclusion Criteria: patients older than 2 years on presentation eyes with previous surgery eyes with secondary glaucoma eyes diagnosed as anterior segment dysgenesis syndrome

Ages Eligible for Study
-----------------
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Visco-Circumferential-Suture-Trabeculotomy<br>Visco-Circumferential-Suture-Trabeculotomy | Procedure: trabeculotomy<br>* performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber<br>|
| Active Comparator: viscotrabeculotomy<br>Viscotrabeculotomy | Procedure: trabeculotomy<br>* performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP | intraocular pressure measuring | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complications | visual devastating complications | 36 months months |
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy

Study Overview
=================
Brief Summary
-----------------
Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of non-arteritic anterior ischemic optic neuropathy (NAION). This study was performed to evaluate the effect of Levodopa-Carbidopa on visual acuity, color vision, and visual field in patients with recent onset NAION (less than 6 weeks duration). Patients and Methods: In this double-blind randomized clinical trial, 13 patients were treated with levodopa-carbidopa and 12 patients took placebo for 3 weeks. Visual acuity, color vision, and visual field were tested before and at 4th, 12th, 16th, and 24th weeks after enrollment, and evaluated.

Official Title
-----------------
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy

Conditions
-----------------
Nonarteritic Anterior Ischemic Optic Neuropathy

Intervention / Treatment
-----------------
* Drug: levodopa-carbidopa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age greater than 50 years old first ophthalmic examination within 6 weeks after onset of disease presence of optic disc swelling followed by optic atrophy within 6 weeks altitudinal, central or generalized visual field defect normal ESR Exclusion Criteria: confirmed giant cell arteritis history of any ocular surgeries optic neuropathy due to acute bleeding advanced diabetic retinopathy uncontrolled glaucoma any ocular disorders that cause visual acuity reduction rather than NAION

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: levodopa-carbidopa|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study of Ovum Donors After Donation

Study Overview
=================
Brief Summary
-----------------
To explore the attitudes and reactions of ovum donors prospectively after ovum donation and to follow their medical histories.

Detailed Description
-----------------
Although several studies have explored donor's reactions and experiences up to a year post donation, no study has explored how donor attitudes and reactions change over time. Currently, there is no long-term data available to describe donor's feelings and reactions to their donation. Consequently, programs have no guidance to counsel prospective donors about whether donors' attitudes change towards their own participation, contact with any offspring, or concerns about the donation. In addition, just as ovum donors' initial health histories were shared anonymously with the recipient(s), any updated information gathered in this study would be shared anonymously with the recipient(s) or offspring should they request those updates.

Official Title
-----------------
A Longitudinal Prospective Study of Ovum Donors After Donation

Conditions
-----------------
Anonymous Donors

Participation Criteria
=================
Eligibility Criteria
-----------------
All anonymous egg donors are eligible for participation.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| egg donors<br>anonymous egg donors | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Do recipients' attitudes and reactions change over time regarding the selection criteria for their donors? | Analysis of recipients' attitudes and reactions at initial psychoeducational consultation, a week after the initial psychoeducational consultion, at donor match and 3 months after delivery | 12-15 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
egg donor
Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease

Study Overview
=================
Brief Summary
-----------------
Hepatitis C virus (HCV) infection causes different disease spectrum ranging from minimal progressive liver disease to cirrhosis or hepatocellular carcinoma. Evidence indicates that host genetic factor may play a role in determining disease progression. It is known that many cytokine polymorphisms affect disease progressin via increasing hepatic fibrosis that are key factors in progressing liver injury. By combinations of fibrosis-relating gene polymorphisms, this study aims to identify patients with high risk for progressive liver disease. These patients need intensive therapy to decrease morbidity and mortality of chronic HCV-related liver disease.

Detailed Description
-----------------
Determination of the following fibrosis-relating gene polymorphisms in HCV-related chronic liver disease and HCC will be performed: TNF-α , TNF-β, Factor V Leiden, TGF-β1, PDGF-B gene, Angiotensinogen (AT),Angiotensin converting enzyme (ACE), microsomal epoxide hydrolase (mEH) and glutathione-S-transferase (GST).

Official Title
-----------------
Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease

Conditions
-----------------
Fibrosis, Chronic Liver Disease

Intervention / Treatment
-----------------
* Genetic: cytokine
* Genetic: cytokine polymorphisms
* Genetic: cytokine polymorphism


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with anti-HCV positive Exclusion Criteria: Anti-HCV-negative patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: cytokine polymorphisms, HCV infection<br>Relate the fibrosis cytokine gene polymorphisms with disease severity of HCV-related chronic liver disease | Genetic: cytokine<br>* polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease<br>* Other names: fibrosis;Genetic: cytokine polymorphisms<br>* Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis<br>* Other names: fibrosis;Genetic: cytokine polymorphism<br>* fibrosis-relating cytokine polymorphism<br>* Other names: fibrosis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cytokine gene polymorphism on disease severity |  | years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hepatitis C virus infection, chronic liver disease, fibrosis-related cytokine
Assessment Of Vascular Health After Niacin Therapy (AVANT)

Study Overview
=================
Brief Summary
-----------------
This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and favorably affect circulating levels of endothelial progenitor cells and microparticles in people with atherosclerotic disease on chronic statin therapy.

Official Title
-----------------
A 12-WEEK STUDY EVALUATING THE EFFECTS OF NIACIN ON VASCULAR HEALTH ASSESSED BY FLUORODEOXYGLUCOSE-PET/CT AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND MICROPARTICLES

Conditions
-----------------
Coronary Artery Disease, Carotid Artery Disease, Peripheral Artery Disease

Intervention / Treatment
-----------------
* Drug: Niacin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men age 55 years and above with coronary artery disease or women age 65 years and above with coronary artery disease OR Men age 45 years and above with both coronary artery disease and carotid or lower extremity peripheral artery disease or women age 55 years and above with both coronary artery disease and carotid or lower extremity peripheral artery disease. Subjects must be on statin monotherapy, defined as a stable statin dose for at least 12 weeks, with no anticipated need for further titration during the study period Exclusion Criteria: Anxiety or claustrophobia prohibiting imaging History of allergy to intravenous contrast, iodine, or shellfish Renal insufficiency History of allergy or severe intolerance to niacin History of diabetes mellitus or elevated fasting glucose Moderate to severe gout Peptic ulcer disease Acute coronary syndrome, transient ischemic attack or cerebrovascular accident, or acute limb ischemia in the preceding 12 months Heart failure or unstable angina pectoris Use of daily non-statin lipid-altering therapy prior to the initiation of study medication

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Niacin<br>Niacin titrated up to 6 grams taken orally every day for 12 weeks | Drug: Niacin<br>* Niacin titrated to 6000 mg daily<br>* Other names: Niacor;|
| Placebo Comparator: Placebo<br>Placebo taken orally every day for 12 weeks | Drug: Placebo<br>* Placebo provided in the same pill quantity as niacin arm<br>* Other names: Sugar pill;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in Arterial Fluorodeoxyglucose (FDG) Uptake Assessed by FDG-PET/CT |  | 12 weeks |
Quality of Preoxygenation in Emergency Surgery

Study Overview
=================
Brief Summary
-----------------
Preoxygenation prior to general anaesthesia prolongs safe apnea time. Proper preoxygenation is always a challenge in emergency surgery. The aim of our study is to estimate problems encountered during preoxygenation, their risk factors and ways of solving them.

Detailed Description
-----------------
Factors, that are associated with compromised preoxygenation will be determined during our study. Pulse oximetry data and end-tidal oxygen concentration values will be evaluated in association with risk factors for insufficient anaesthesia face mask seal, difficult intubation, preoxygenation techniques used, comorbidities, physical status, hemodynamic and laboratory measures. Parameters analysed: Preoperative: medical history, physical examination, laboratory findings, anthropometric data Intraoperative: preoxygenation equipment and method used (defined by anaesthesiologist in charge of the case), oxygenation and haemodynamic values recorded during preoxygenation and induction of anaesthesia, intraoperative laboratory values (if obtained)

Official Title
-----------------
Study of Preoxygenation Quality Prior to General Anesthesia in Emergency Surgery

Conditions
-----------------
Preoxygenation, Anaesthesia, Emergencies, Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: written informed consent patient going for emergency surgery under general anaesthesia age > 18 years Exclusion Criteria: informed consent refusal noneligible for preoxygenation before general anaesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficient preoxygenation in preset time | End-tidal oxygen concentration values | 300 seconds | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Factors influencing preoxygenation quality | Medical history, physical status, lab findings, preoxygenation equipment and method | 300 seconds | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anaesthesia, Preoxygenation
Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography

Study Overview
=================
Brief Summary
-----------------
This study aims to characterize patient experience, satisfaction and preference for use of the QT Scanner in comparison to mammography by directly engaging women who have experience with both technologies.

Detailed Description
-----------------
The objectives will be addressed by first conducting structured one-on-one interviews with about 20 women (Qualitative Phase), and then administering a web-based patient survey with quantitative measurements in about 200 women (Quantitative Phase). The current Protocol registration pertains to the first, qualitative phase of the study.

Official Title
-----------------
Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography

Conditions
-----------------
Breast Cancer Screening

Intervention / Treatment
-----------------
* Diagnostic Test: QT Scanner


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have used the QT Scanner Have used mammography Speak English Willing to provide consent and participate in the survey Exclusion Criteria: • Excluded if all Inclusion Criteria are not met
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| QT Scanner in comparison to mammography<br>Women who have experience with both technologies (QT Scanner/Breast mammography | Diagnostic Test: QT Scanner<br>* Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.<br>* Other names: Quantitative Transmission Ultrasound Breast Scanner-1;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative phase: structured one-on-one interviews | one-on-one interviews will be conducted by trained professionals with about 20 women | 30 days |
Evaluation of Pain Reduction After Hemorrhoidectomy With Use of Diltiazim Ointment 2%

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effectiveness of diltiazem ointment 2 percent in reducing pain after hemorrhoidectomy.

Detailed Description
-----------------
Pain after hemorrhoidectomy remains a major postsurgical complication.Therefore pain management in patients is an important goal.Many studies have focused on surgical techniques,preoperative and postoperative regimes.We assessed a randomised double blind placebo-controlled trial to evaluate the effect of diltiazem ointment after surgery.

Official Title
-----------------
Evaluation of Pain Reduction After Hemorrhoidectomy With Use of Diltiazim Ointment 2%

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Diltiazem


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with grade 3 or 4 hemorrhoid who underwent Milligan-Morgan surgery. Exclusion Criteria: Patients with a history of heart disease, blood pressure, orthostatic hypertension, hemorrhoidal surgery,or those who had previous adverse effect from calcium channel blocker drugs and also those who were pregnant.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diltiazem<br> | Drug: Diltiazem<br>* 2%,3 times daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of Pain |  | daily in one week |